Protein kinase R: A novel mediator of articular cartilage degradation in arthritis

Current Rheumatology Reviews

Volumn 2, Issue 1, 2006, Pages 9-21

  Gilbert, Sophie J ^a   Duance, Victor C ^a   Mason, Deborah J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Arthritis; Articular cartilage; Ceramide; Matrix metalloproteinase; PKR; TNF

Indexed keywords

CERAMIDE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE R; SCLEROPROTEIN; SMALL INTERFERING RNA; SPHINGOLIPID; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTHRITIS; ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL DEATH; DRUG EFFICACY; GENE ACTIVATION; HUMAN; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STRESS; UPREGULATION;

EID: 33745922351     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339706775697026     Document Type: Review

References (138)

1. Gilbert SJ, Duance VC, Mason DJ. Tumour necrosis factor α up-regulates protein kinase R (PKR)-activating protein (PACT) and increases phosphorylation of PKR and eukaryotic initiation factor2-α in articular chondrocytes. Biochem Soc Trans 2002; 30: 886-9.
2. Wei L, Svennson O, Hjerpe A. Correlation of morphologic and biochemical changes in the natural history of spontaneous osteoarthrosis in guinea pigs. Arthritis Rheum 1997; 40: 2075-83.
3. Wei L, de Bri E, Lundberg A, Svennson O. Mechanical load and primary guinea pig osteoarthrosis. Acta Orthop Scand 1998; 69: 351-7.
4. Der SD, Yang YL, Weissmann C, William BR. A double-stranded RNA-activated protein kinase-dependant pathway mediating stress-induced apoptosis. Proc Natl Acad Sci USA 1997; 94: 8841-45.
5. Zamanian-Daryoush M, Mogensen TH, DIDonato JA, Williams BRG. NF-kB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kB-inducing kinase and IkB kinase. Mol Cell Biol 2000; 20: 1278-90.
6. Cheshire JL, Williams BRG, Baldwin AS Jr. Involvement of double-stranded RNA-activated protein kinase in the synergistic activation of nuclear factor-kB by turnour necrosis factor-α and γ-interferon in preneuronal cells. J Biol Chem 1999; 274: 4801-06.
7. Goldring MB. Osteoarthritis and cartilage: The role of cytokines. Curr Rheumatol Rep 2000; 2: 459-65.
8. Murphy G, Knauper V, Atkinson S, et al. Matrix metalloproteinases in arthritic disease. Arthritis Res 2002; 4. S39-49. Epub 2002 May 9.
9. Nagase H, Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 2003; 5: 94-103. Epub 2003 Feb 14.
10. Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JF, Jr. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989; 84: 678-85.
11. Aigner T, Zien A, Gehrsitz A, Gebhard PM, McKenna L. Anabolic and catabolic gene expression pattern analysis in normal versus osteoarthritic cartilage using complementary DNA-array technology. Arthritis Rheum 2001; 44: 2777-89.
12. Yoshihara Y, Nakamura H, Obata K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000; 59: 455-61.
13. Westacott CI, Barakat AF, Wood L, et al. Tumour necrosis factor-alpha can contribute to focal loss of cartilage in osteoarthritis. Osteoarthr Cartil 2000; 8: 213-21.
14. Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 1999; 40: 1-11.
15. Westacott CI, Whicher JT, Barnes IC, Thompson D, Swan AJ, Dieppe PA. Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis 1990; 49: 676-81.
16. Feldmann M, Maini RN. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 1999; 38 (Suppl. 2):3-7.
17. Amin AR. Regulation of tumour necrosis factor-alpha and tumour necrosis factor converting enzyme in human osteoarthritis. Osteoarthritis Cartilage 1999; 7: 392-4.
18. Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthtitis: suppression of collagenase-1 expression. Arthritis Rheum 1996; 39: 1535-44.
19. Katz Y, Nadiv O, Beer Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflamamation processes. Arthritis Rheum 2001; 44: 2176-84.
20. Hwang S-Y, Kim J-Y, Kim K-W, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NFkB- and P13-kinase/Akt-dependent pathways. Arthritis Res Ther 2004; 6: R120-28. Epub 2004 Jan 21.
21. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P. JAK/STAT but not ERK1/ ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem 2003; 278: 2903-12. Epub 2002 Nov 4.
22. Flannery CR, Little CB, Hughes CE, Curtis CL, Caterson B, Jones SA. IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol 2000; 19: 549-53.
23. Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187: 461-8.
24. Boe A, Baiocchi M, Carbonatto M, Papoian R, Serlupi-Crescenzi O. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 1999; 11: 1057-64.
25. Pelletier J-P, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease. Potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001; 44: 1237-47.
26. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2: 244-7.
27. Feldmann M, Maini RN. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-96.
28. Tugwell P. Pharmacoeconomics of drug therapy for rheumatoid arthritis. Rheumatology 2000; 39, (Suppl. 1): 43-7.
29. Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev 2003; 2: 346-57.
30. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-α therapies: the next generation. Nat Rev Drug Discov 2003; 2: 736-46.
31. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 2003; 48: 3308-19.
32. Clemens MJ, Elia A. The double-stranded RNA-dependant protein kinase PKR: structure and function. J Interferon Cytokine Res 1997; 17: 503-24.
33. Williams BR. PKR; a sentinel kinase for cellular stress. Oncogene 1999; 18: 6112-20.
34. Jimenez-Garcia LF, Green SR, Mathews MB, Spector DL. Organization of the double-stranded RNA-activated protein kinase DAI and virus-associated VA RNAI in adenovirus-2-infected HeLa cells. J Cell Sci 1993; 106: 11-22.
35. Jeffrey IW, Kadereit S, Meurs EF, et al. Nuclear localization of the interferon-inducible protein kinase PKR in human cells and transfected mouse cells. Exp Cell Res 1995; 218: 17-27
36. Besse S, Rebouillat D, Marie I, Puvion-Dutilleul F, Hovanessian AG. Ultrastructural localization of interferon-inducible double-stranded RNA-activated enzymes in human cells. Exp Cell Res 1998; 239: 379-92.
37. Peters GA, Hartmann R, Qin J, Sen GC. Modular structure of PACT: distinct domains for binding and activating PKR. Mol Cell Biol 2001; 21: 1908-20.
38. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8: 237-49.
39. Gil J, Alcami J, Esteban M. Induction of apoptosis by double-stranded-RNA-dependent protein kinase (PKR) involves the alpha subunit of eukaryotic translation initiation factor 2 and NF-kappaB. Mol Cell Biol 1999; 19: 4653-63.
40. Jeffrey IW, Bushell M, Tilleray VJ, Morley S, Clemens MJ. Inhibition of protein synthesis in apoptosis: differential requirements by the tumor necrosis factor alpha family and a DNA-damaging agent for caspases and the double-stranded RNA-dependent protein kinase. Cancer Res 2002; 62: 2272-80.
41. Goh KC, deVeer MJ, Williams BR. The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin. EMBO J 2000; 19: 4292-7.
42. Yeung MC, Liu J, Lau AS. An essential role for the interferon-inducible, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells. Proc Natl Acad Sci USA 1996; 93: 12451-55.
43. Mundschau LJ, Faller DV. Platelet-derived growth factor signal transduction through the interferon-inducible kinase PKR. J Biol Chem 1995; 270: 3100-06.
44. Deb A, Haque SJ, Mogensen T, Silverman RH, Williams BR. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STATI-independent pathway. J Immunol 2001; 166: 6170-80.
45. Ito T, Yang M, May WS. Rax, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling. J Biol Chem 1999; 274: 15427-32.
46. Patel CV, Handy I, Goldsmith T, Patel RC. PACT, a stress-modulated cellular activator of interferon-induced, double-stranded RNA activated protein kinase, PKR. J Biol Chem 2000; 275: 37993-8.
47. Serhan CN, Haeggstrom JZ, Leslie CC. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J 1996; 10: 1147-58.
48. Ruvolo PP, Gao, FG, Blalock WL, Deng X, Stratford May W. Ceramide regulates protein synthesis by a novel mechanism involving the cellular PKR activator RAX. J Biol Chem 2001; 276: 11754-8. Epub 2001 Jan 8.
49. Ruvolo PP. Intracellutar signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 2003; 47: 383-92.
50. Goni FM, Alonso A. Sphingomyelinases: enzymology and membrane activity. FEBS Lett 2002; 531: 38-46.
51. Gilbert SJ, Duance VC, Mason DJ. Does protein kinase R mediate TNF-α- and ceramide-induced increases in expression and activation of matrix metalloproteinases in articular cartilage by a novel mechanism? Arthritis Res Ther 2004; 6: R46-R55. Epub 2003 Nov 12.
52. Salzberg S, Mandelboim M, Zalcberg M, Shainberg A, Mandelbaum M [corrected to Mandelboim M]. Interruption of myogenesis by transforming growth factor beta 1 or EGTA inhibits expression and activity of the myogenic-associated (2'-5') oligoadenylate synthetase and PKR. Exp Cell Res 1995; 219: 223-32. Erratum in: Exp Cell Res 1995; 220: 509
53. Silva AM, Whitmore M, Xu Z, Jiang Z, Li X, Williams BR. Protein kinase R (PKR) interacts with and activates mitogen-activated protein kinase kinase 6 (MKK6) in response to double-stranded RNA stimulation. J Biol Chem 2004; 279: 37670-6. Epub 2004 Jun 30.
54. Wong AH, Tam NW, Yang YL, Cuddihy AR, Li S, Kirchhoff S, Hauser H, Decker T, Koromilas AE. Physical association between STAT1 and the interferon-inducible protein kinase PKR and implications for interferon and double-stranded RNA signaling pathways. EMBO J 1997; 16: 1291-304.
55. Tam NW, Ishii T, Li S, Wong AH, Cuddihy AR, Koromilas AE. Upregulation of STAT1 protein in cells lacking or expressing mutants of the double-stranded RNA-dependent protein kinase PKF. Eur J Biochem 1999; 262: 149-54.
56. Cuddihy AR, Wong AH, Tam NW, Li S, Koromilas AE. The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene 1999; 18:2690-702.
57. Meurs E, Chong K, Galabru J, et al. Molecular cloning and characterization of cDNA encoding human double-stranded RNA activated protein kinase induced by interferon. Cell 1990; 62: 379-90
58. Patel RC, Stanton P, McMillan NM, Williams BF, Sen GC. The interferon-inducible double-stranded RNA-activated protein kinase self-associates in vitro and in vivo. Proc Natl Acad Sci USA 1995; 92: 8283-7.
59. Huang X, Hutchins B, Patel RC. The C-terminal, third conserved motif of the protein activator PACT plays an essential role in the activation of double-stranded-RNA-dependent protein kinase (PKR). Biochem J 2002; 366: 175-86.
60. Lee SB, Green SR, Mathews MB, Esteban M. Activation of the doubte-stranded RNA (dsRNA)-activated human protem kinase in vivo in the absence of its dsRNA binding domain. Proc Natl Acad Sci USA 1994; 91: 10551-5.
61. Zhu S, Romano PR, Wek RC. Ribosome targeting of PKR is mediated by two double-stranded RNA-binding domains and facilitates in vivo phosphorylation of eukaryotic initiation factor-2. J Biol Chem 1997; 272: 14434-41.
62. Vattem KM, Staschke KA, Wek RC. Mechanism of activation of the double-stranded-RNA-dependent protein kinase, PKR: role of dimerization and cellular localization in the stimulation of PKR phosphorylation of eukaryotic initiation factor-2 (eIF2). Eur J Biochem 2001; 268: 3674-84.
63. Raine DA, Jeffrey IW, Clemens MJ. Inhibition of the double-stranded RNA-dependent protein kinase PKR by mammalian ribosomes. FEBS Lett 1998; 436: 343-8.
64. Wu S, Kumar KU, Kaufman RJ. Identification and requirement of three ribosome binding domains in dsRNA-dependent protein kinase (PKR). Biochemistry 1998; 37: 13816-26.
65. Nussbaum JM, Gunnery S, Mathews MB. The 3'-untranslated regions of cytoskeletal muscle mRNAs inhibit translation by activating the double-stranded RNA-dependent protein kinase PKR. Nucleic Acids Res 2002; 30: 1205-12.
66. Romano PR, Garcia-Barrio MT, Zhang X, et al. Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2alpha kinases PKR and GCN2. Mol Cell Biol 1998; 18: 2282-97.
67. Thomis DC, Samuel CE. Mechanism of interferon action: evidence for intermolecular autophosphorylation and autoactivation of the interferon-induced, RNA-dependent protein kinase PKR. J Virol 1993; 67: 7695-700.
68. Cosentino GP, Venkatesan S, Serluca FC, Green SR, Mathews MB, Sonenberg N. Double-stranded-RNA-dependent protein kinase and TAR RNA-binding protein form homo- and heterodimers in vivo. Proc Natl Acad Sci USA 1995; 92: 9445-9.
69. Wu S, Kaufman RJ. Double-stranded (ds) RNA binding and not dimerization correlates with the activation of the dsRNA-dependent protein kinase (PKR). J Biol Chem 1996; 271: 1756-63.
70. Vattem KM, Staschke KA, Zhu S, Wek RC. Inhibitory sequences in the N-terminus of the double-stranded-RNA-dependent protein kinase, PKR, are important for regulating phosphorylation of eukaryotic initiation factor 2alpha (eIF2alpha). Eur J Biochem 2001; 268: 1143-53.
71. Wu S, Kaufman RJ. A model for the double-stranded RNA (dsRNA)-dependent dimerization and activation of the dsRNA-activated protein kinase PKR. J Biol Chem 1997; 272: 1291-6.
72. Clemens MJ, Bushell M, Jeffrey IW, Pain VM, Morley SJ. Translation initiation factor modifications and the regulation of protein synthesis in apoptotic cells. Cell Death Differ 2000; 7: 603-15.
73. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809
74. Thomis DC, Samuel CE. Mechanism of interferon action: autoregulation of RNA-dependent P1/eIF-2 alpha protein kinase (PKR) expression in transfected mammalian cells. Proc Nad Acad Sci USA 1992; 89: 10837-41.
75. Barber GN, Wambach M, Wong ML, Dever TE, Hinnebusch AG, Katze MG. Translational regulation by the interferon-induced double-stranded-RNA-activated 68-kDa protein kinase. Proc Natl Acad Sci USA 1993; 90: 4621-5.
76. 1-untranslated region of human TNF-alpha mRNA renders splicing dependent on the activation of protein kinase PKR. Genes Dev 1999; 13: 3280-93.
77. Ben-Asouli Y, Banai Y, Pel-Or Y, Shir A, Kaempfer R. Human interferon-gamma mRNA autoregulates its translation through a pseudoknot that activates the interferon-inducible protein kinase PKR. Cell 2002; 108: 221-32.
78. Kaempfer R. RNA sensors: novel regulators of gene expression. EMBO Rep 2003; 4: 1043-7.
79. Jarrous N, Osman F, Kaempfer R. 2-Aminopurine selectively inhibits splicing of tumor necrosis factor alpha mRNA. Mol Cell Biol 1996; 16: 2814-22.
80. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 834-9. Epub 2003 Aug 24.
81. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34: 263-4.
82. Moss EG, Taylor JM. Small-interfering RNAs in the radar of the interferon system. Nat Cell Biol 2003; 5: 771-2.
83. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001; 98: 9742-7. Epub 2001 Jul 31.
84. Schmedt C, Green SR, Manche L, Taylor DR, Ma Y, Mathews MB. Functional characterization of the RNA-binding domain and motif of the double-stranded RNA-dependent protein kinase DAI (PKR). J Mol Biol 1995; 249: 29-44.
85. Patel RC, Stanton P, Sen GC. Role of the amino-terminal residues of the interferon-induced protein kinase in its activation by double-stranded RNA and heparin. J Biol Chem 1994; 269: 18593-8.
86. Patel RC, Sen GC. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J 1998; 17: 4379-90.
87. Gupta V, Patel RC. Proapoptotic protein PACT is expressed at high levels in colonic epithelial cells in mice. Am J Physiol Gastrointest Liver Physiol 2002; 283: G801-8.
88. Bennett RL, Blalock WL, May WS. Serine 18 Phosphorylation of RAX, the PKR Activator, Is Required for PKR Activation and Consequent Translation Inhibition. J Biot Chem 2004; 279: 42687-93. Epub 2004 Aug 6.
89. Saelens X, Kalai M, Vandenabeele P. Translation inhibition in apoptosis: caspase-dependent PKR activation and eIF2-alpha phosphorylation. J Biol Chem 2001; 276: 41620-8. Epub 2001 Sep 12.
90. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000; 12: 1-13.
91. Chu W-M, Ostertag D, Li Z-W, et al. JNK2 and IKKβ are required for activating the innate response to viral infection. Immunity 1999; 11: 721-31.
92. Gil J, Alcami J, Esteban M. Activation of NF-kappa B by the dsRNA-dependent protein kinase, PKR involves the I kappa B kinase complex. Oncogene 2000; 19: 1369-78.
93. Maran A, Maitra RK, Kumar A, et al. Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 1994; 265: 789-92.
94. Kumar A, Haque J, Lacoste J, Hiscott J, Williams BR. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc Natl Acad Sci USA 1994; 91: 6288-92.
95. Baeuerle PA. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 1998; 95: 729-31.
96. Thanos D, Maniatis T. Identification of the rel family members required for virus induction of the human beta interferon gene. Mol Cell Biol 1995; 15: 152-64.
97. Gil J, Rullas J, Garcia MA, Alcami J, Esteban M. The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-kappaB activation. Oncogene 2001; 20: 385-94.
98. Baltzis D, Li S, Koromilas AE. Functional characterization of pkr gene products expressed in cells from mice with a targeted deletion of the N terminus or C terminus domain of PKR. J Biol Chem 2002; 277: 38364-72. Epub 2002 Aug 2.
99. Yang YL, Reis LF, Pavlovic J, et al. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J 1995; 14: 6095-106.
100. Kumar A, Yang YL, Flati V, et al. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB. EMBO J 1997; 16: 406-16.
101. Abraham N, Stojdl DF, Duncan PI, et al. Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. J. Biol Chem 1999; 274: 5953-62.
102. Iordanov MS, Paranjape JM, Zhou A, et al. Activation of p38 mitogen-activated protein kinase and c-Jun NH(2)-terminal kinase by double-stranded RNA and encephalomyocarditis virus: involvement of RNase L, protein kinase R, and alternative pathways. Mol Cell Biol 2000; 20: 617-27.
103. Bonnet MC, Weil R, Dam E, Hovanessian AG, Meurs EF. PKR stimulates NF-kappaB irrespective of its kinase function by interacting with the IkappaB kinase complex. Mol Cell Biol 2000; 20: 4532-42.
104. Srivastava SP, Kumar KU, Kaufman RJ. Phosphorylation of eukaryotic translation initiation factor 2 mediates apoptosis in response to activation of the double-stranded RNA-dependent protein kinase. J Biol Chem 1998; 273: 2416-23.
105. Kaufman RJ, Davies MV, Pathak VK, Hershey JW. The phosphorylation state of eucaryotic initiation factor 2 alters translational efficiency of specific mRNAs. Mol Cell Biol 1989; 9: 946-58.
106. Tan SL, Katze MG. The emerging role of the interferon-induced PKR protein kinase as an apoptotic effector: a new face of death? J Interferon Cytokine Res 1999; 19: 543-54.
107. Yeung MC, Lau AS. Tumor suppressor p53 as a component of the tumor necrosis factor-induced, protein kinase PKR-mediated apoptotic pathway in human promonocytic U937 cells. J Biol Chem 1998; 273: 25198-202.
108. Donzé O, Deng J, Curran J, Sladek R, Picard D, Sonenberg N. The protein kinase PKR: a molecular clock that sequentially activates survival and death programmes. EMBO J 2004; 23: 564-71. Epub 2004 Jan 29.
109. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-90.
110. Amer EC, Hughes CE, Decicco CP, Caterson B, Tortorella MD. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthr Cartil 1998; 6: 214-28.
111. Little CB, Flannery CR, Hughes CE, Mort JS, Roughley PJ, Dent C, Caterson B. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem J 1999; 344: 61-8.
112. Reunanen N, Westermarck J, Hakkinen L, Holmstrom TH, Elo I, Eriksson JE, Kahari VM. Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. J Biol Chem 1998; 273: 5137-45.
113. Laulederkind SJ, Bielawska A, Raghow R, Hannun YA, Ballou LR. Ceramide induces interleukin 6 gene expression in human fibroblasts. J Exp Med 1995; 182: 599-604.
114. Buisson-Legendre N, Bernard P, Bobichon H, et al. Involvement of the 92-kDa gelatinase (matrix metalloproteinase-9) in the ceramide-mediated inhibition of human keratinocyte growth. Biochem Biophys Res Commun 1999; 260: 634-40.
115. Sabatini M, Rolland G, Leonce S, et al. Effects of ceramide on apoptosis, proteoglycan degradation, and matrix metalloproteinase expression in rabbit articular cartilage. Biochem Biophys Res Commun 2000; 267: 438-44.
116. Sabatini M, Thomas M, Deschamps C, et al. Effects of ceramide on aggrecanase activity in rabbit articular cartilage. Biochem Biophys Res Commun 2001; 283: 1105-10.
117. Hu Y, Conway TW. 2-Aminopurine inhibits the double-stranded RNA-dependent protein kinase both in vitro and in vivo. J Interferon Res 1993; 13: 323-8.
118. Pataer A, Vorburger SA, Barber GN, et al. Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). Cancer Res 2002; 62: 2239-43.
119. Williams BR, Signal integration via PKR. Sci STKE 2001; 89: RE2.
120. Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-kB in human inflamed synovial tissue. Arthritis Rheum 1996; 39: 583-91.
121. Sakai T, Kambe F, Mitsuyama H, et al. Tumour necrosis factor a induces expression of genes for matrix degradation in human chondrocyte-like HCS-2/8 cells through activation of NF-kB: abrogation of the tumour necrosis factor a effect by proteasome inhibitors. J Bone Miner Res 2001; 16: 1272-80.
122. Bondeson J, Brennan F, Foxwell B, Feldman M. Effective adenoviral transfer of IkBα into human fibroblasts and chondrosarcoma. cells reveals that the induction of matrix metalloproteinases and proinflaminatory cytokines is nuclear factor-kB dependent. J Rheumatol 2000; 27: 2078-89.
123. Murakami S, Lefebvre V, de Crombrugghe B. Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumour necrosis factor-α J Biol Chem 2000; 275: 3687-92.
124. Huang W, Zhou X, Lefebvre V, de Crombrugghe B. Phosphorylation of SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9's ability to transactivate a Col2a1 chondrocyte-specific enhancer. Mol Cell Biol 2000; 20: 4149-58. Erratum in: Mol Cell Biol 2000 Oct;20(20):7838.
125. Sekiya I, Tsuji K, Koopman P, et al. SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. J Biol Chem 2000; 275: 10738-44.
126. Zakany R, Szucs K, Bako E, et al. Protein phosphatase 2A is involved in the regulation of protein kinase A signaling pathway during in vitro chondrogenesis. Exp Cell Res 2002; 275: 1-8.
127. Pham FH, Sugden PH, Clerk A. Regulation of protein kinase B and 4E-BP01 by oxidative stress in cardiac myocytes. Circ Res 2000; 86: 1252-8.
128. Xu Z, Williams BR. The B56alpha regulatory subunit of protein phosphatase 2A is a target for regulation by double-stranded RNA-dependent protein kinase PKR. Mol Cell Biol 2000; 20: 5285-99.
129. Chen SC, Kramer G, Hardesty B. Isolation and partial characterization of an Mr 60,000 subunit of a type 2A phosphatase from rabbit reticulocytes. J Biol Chem 1989; 264: 7267-75.
130. Arner EC. Aggrecanase-mediated cartilage degradation. Curr Opin Pharmacol 2002; 2: 322-9.
131. Little CB, Mittaz L, Belluoccio D et al. ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. Arthritis Rheum 2005; 52:1461-72.
132. Aigner T, Kim HA. Apoptosis and cellular vitality. Issues in osteoarthritic cartilage degeneration. Arthritis Rheum 2002; 46: 1986-96.
133. Sharif M, Whitehouse A, Sharman P, Perry M, Adams M. Increased apoptosis in human osteoarthritic cartilage corresponds reduced cell density and expression of caspase-3. Arthritis Rheum 2004; 50: 507-15.
134. Blanco FJ, Guitian R, Vazquez-Martul E, de Toro FJ, Galdo F. Osteoarthritis chondrocytes die by apoptosis: a possible pathway for osteoarthritis pathology. Arthritis Rheum 1998; 41: 284-9.
135. Hashimoto S, Ochs RL, Komiya S, Lotz M. Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. Arthritis Rheum 1998; 41: 1632-8.
136. Kouri JB, Rosales-Encina JL, Chaudhuri PP, Luna J, Mena R. Apoptosis in human osteoarthritic cartilage: a microscopy report. Med Sci Res 1997; 25: 245-8.
137. Nuttall ME, Nadeau DP, Fisher PW, et al. Inhibition of caspase-3-like activity prevents apoptosis while retaining functionality of human chondrocytes in vitro. J Orthop Res 2000; 18: 356-63.
138. Meusel TR, Kehoe KE, Imani F. Protein kinase R regulates doubles-tranded RNA induction of TNF-alpha but not EL-1 beta mRNA in human epithelial cells. J Immunol 2002; 168: 6429-35.